A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Clinical trial NCT07432022 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07432022
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-01
- Primary completion
- 2028-06-30
- Enrollment
- 115
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.